Advertisement
U.S. markets closed

Corbus Pharmaceuticals Holdings, Inc. (CRBP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
39.24+3.67 (+10.32%)
At close: 04:00PM EDT
39.62 +0.38 (+0.97%)
After hours: 07:36PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close35.57
Open35.42
Bid39.06 x 100
Ask39.39 x 100
Day's Range35.16 - 39.96
52 Week Range3.03 - 49.87
Volume234,856
Avg. Volume945,380
Market Cap411.749M
Beta (5Y Monthly)2.43
PE Ratio (TTM)N/A
EPS (TTM)-10.31
Earnings DateMay 07, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est55.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CRBP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Corbus Pharmaceuticals Holdings
    SMG: Raising target price to $64.00SCOTTS MIRACLE-GRO CO has an Investment Rating of SELL; a target price of $64.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update

    Encouraging CRB-701 (SYS6002) First-in-Human Data Presented at ASCO-GU 2024; first patient expected to be dosed in US Ph1 study by end of March 2024 IND Application for CRB-601 cleared; Ph1 study on track to commence in Summer of 2024Pre-clinical data for CRB-913 presented at Obesity Week; IND filing on track by the end of 2024$127M of cash & investments at February 2, 2024; 3+ years of projected runway through Q1 2027Appointed Dr. Dominic Smethurst as Chief Medical Officer NORWOOD, Mass., March

  • GlobeNewswire

    Corbus Pharmaceuticals to Participate in the BMO Capital Markets Inaugural Obesity Summit

    NORWOOD, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a panel discussion at BMO Capital Markets Inaugural BMO Obesity Summit to be held on March 20, 2024 in New York City, NY. Details of the panel discussion are as follow: BMO Capital Markets Inaugural Obesity SummitPanel Title: Emerging Therapeutics LandscapeDate: Wednesda

  • GlobeNewswire

    Corbus Pharmaceuticals Appoints Dr. Dominic Smethurst as Chief Medical Officer

    NORWOOD, Mass., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the appointment of Dr. Dominic Smethurst, MA MRCP, as the Company’s Chief Medical Officer (CMO). In this role, Dr. Smethurst will lead the clinical development of the Company’s investigational oncology drugs: CRB-701, a next generation Nectin-4 targeting antibody drug conjugate (ADC) develope